We also observed that CDKN2B‐AS1 expression correlated with tumour growth in HCC patients, with the CDKN2B‐AS1‐associated pathway in HCC involving E2F targets and the cell cycle. Here, CDKN2B is linked to hepatocellular carcinoma.